RxDoctor Payments Data

Lisa Kleindorfer

Adult Health · Indianapolis, INNPI 1205912995

Payments from drug & device makers

$1,530in general payments, 2019–2025

Across 87 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Novartis$252
  • Astellas Pharma US Inc$145
  • Lilly USA, LLC$145
  • Novo Nordisk$80
  • Glaukos Corporation$64
  • plus $460 from 14 others

What the payments were for

  • Food & beverage$1,530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,530 in reported general payments places this provider in the 75th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$17,512
Medicare patients
109
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$25,781
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,859
Albuterol Sulfate HfaAlbuterol Sulfate17$793
Levothyroxine Sodium61$474
Potassium Chloride18$450
Amlodipine Besylate58$422
Atorvastatin Calcium48$419
Losartan Potassium26$342
Lisinopril31$282
Omeprazole18$233
Cefdinir13$231
Atenolol15$212
Buspirone Hcl12$181
Allopurinol12$178
Metoprolol Succinate20$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$80$25,78125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 adult health providers in Indiana.

Other adult health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →